Drug Trial Radar · NCT04048135
A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
Last checked: Nov 19, 2026Latest source record: Apr 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Jul 29, 2019
Primary completion
Aug 28, 2020
Study completion Jan 19, 2022
Sponsor
- Lead sponsor
- 89bio, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ProSciento, Inc.
- First posted
- Aug 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part 1: This is a multi-center evaluation of pegozafermin (administered weekly or every other week) in a randomized, double-blind, placebo-controlled study administered for 12 weeks in participants with NASH and NAFLD at high risk of NASH, including a pre-defined number of participants with biopsy confirmed NASH and fibrosis stages F1-F3 to be enrolled. Part 2: This is a multi-center, open label evaluation of pegozafermin at 27 mg administered weekly for 20 weeks in participants with biopsy-proven NASH (NAS ≥4, fibrosis stage F2 or F3).
Conditions
- NASH
Interventions
PegozaferminDrug
Subcutaneous injection
PlaceboOther
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs)Time frame: Up to 113 days
- Part 2: Number of Participants With TEAEsTime frame: Up to 162 days
- Part 1: Maximum Observed Serum Concentration (Cmax) of PegozaferminTime frame: Predose and up to 168 hours postdose on Day 29
- Part 1: Area Under the Serum Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUClast) of PegozaferminTime frame: Predose and up to 168 hours postdose on Day 29
- Part 1: Time to Peak Serum Concentration (Tmax) of PegozaferminTime frame: Predose and up to 168 hours postdose on Day 29
- Part 1: Terminal Elimination Half-life (t1/2) of PegozaferminTime frame: Predose and up to 168 hours postdose on Day 29
- Part 2: Number of Participants With at Least a 2-point Improvement in NAFLD Activity Score (NAS) With at Least a 1-point Improvement in Ballooning or Lobular Inflammation, and no Worsening of FibrosisTime frame: Day 141
Locations
26 sites in 2 countries. Site status is shown where the registry gives one.
89bio Clinical Study Site
Madison, Alabama
89bio Clinical Study Site
Chandler, Arizona
89bio Clinical Study Site
Tucson, Arizona
89bio Clinical Study Site
Chula Vista, California
89bio Clinical Study Site
Huntington Beach, California
89bio Clinical Study Site
Montclair, California
89bio Clinical Study Site
Miami, Florida
89bio Clinical Study Site
Miami Lakes, Florida
89bio Clinical Study Site
Ocala, Florida
89bio Clinical Study Site
Sarasota, Florida
89bio Clinical Study Site
Lake Charles, Louisiana
89bio Clinical Study Site
Berlin, New Jersey
89bio Clinical Study Site
Florham Park, New Jersey
89bio Clinical Study Site
East Syracuse, New York
89bio Clinical Study Site
Concord, North Carolina
89bio Clinical Study Site
Raleigh, North Carolina
89bio Clinical Study Site
Greenwood, South Carolina
89bio Clinical Study Site
Summerville, South Carolina
89bio Clinical Study Site
Hermitage, Tennessee
89bio Clinical Study Site
Austin, Texas
89bio Clinical Study Site
Edinburg, Texas
89bio Clinical Study Site
Houston, Texas
89bio Clinical Study Site
San Antonio, Texas
89bio Clinical Study Site
San Antonio, Texas
89bio Clinical Study Site
Wichita Falls, Texas
89bio Clinical Study Site
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.